AUTHORS
Susan Bal, MD, Murali Janakiram, MBBS2, Laura Joiner, PharmD, BCOP3, Luciano J. Costa, MD, PhD4, Carlyn Rose Tan, MD5, Saad Z. Usmani, MD6, Myo Htut, MD7, Saurabh Zanwar, MBBS, MD8, Mrugakshi Dave, MS9, Chiung-Yu Huang, PhD10, Hira Mian, MD11, Alissa Visram, MD, MPH12, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD13, Tebereh Mesfin14, Roman Hajek, MD, PhD15, Jana Mihalyova, MD16, Joaquin Martinez-Lopez Sr, MD, PhD17, Alberto Blanco, MD18, Chandramouli Nagarajan, MD, MBBS, FRCP, FRCPath19, Efstathios Kastritis, MD20, Wee-Joo Chng Jr, MD, PhD, MBBS, FRCP, FRCPath21, Laurent Garderet22, Juan Du, MD, PhD23, Kihyun Kim, MD, PhD24, Hermann Einsele, MD, PhD25, Paula Rodriguez Otero, MD, PhD26, Yi Lin Jr, MD, PhD27, Thomas Martin, MD28, Amrita Krishnan, MD, FACP29
AFFILIATIONS
1 University of Alabama at Birmingham, Birmingham, Alabama, United States
2 City of Hope, Duarte, California, United States
3 University of Alabama at Birmingham, Birmingham, Alabama, United States
4 University of Alabama at Birmingham, Birmingham, Alabama, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 City of Hope, Duarte, California, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 International Myeloma Foundation, Studio City, California, United States
10 University of California San Francisco, San Francisco, California, United States
11 McMaster University, Hamilton, Ontario, Canada
12 Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada
13 The London Hospital Medical College, London, United Kingdom
14 The London Hospital Medical College, London, United Kingdom
15 University of Ostrava, Ostrava, Czech Republic
16 University of Ostrava, Ostrava, Czech Republic
17 Hospital 12 de Octubre, Complutense University, CNIO, Madrid, Spain
18 Hospital Universitario 12 De Octubre, Madrid, Spain
19 Singapore General Hospital and National Cancer Centre Singapore, Singapore, Singapore
20 National and Kapodistrian University Of Athens, Athens, Greece
21 National University Cancer Institute, Singapore, Singapore
22 Hôpital Universitaire de la Pitié-Salpêtrière, Paris, France
23 Shanghai Renji Hospital, Shanghai, China
24 Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea, Rep. of South
25 University Hospital Würzburg, Würzburg, Germany
26 Cancer Center Clínica Universidad de Navarra (CCUN), CIMA, CIBERONC, IDISNA,, Pamplona, Spain
27 Mayo Clinic, Rochester, Minnesota, United States
28 UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
29 City of Hope, Duarte, California, United States
ABSTRACT
Background
Talquetamab, a GPRC5D×CD3 bispecific antibody, is approved for treatment of relapsed/refractory multiple myeloma (RRMM). Translocation t(11;14), the most common IgH translocation in myeloma, with unique clinical, predictive, and prognostic characteristics, is associated with lower GPRC5D expression in preclinical data (Lee et al. Nature Medicine 2026), raising the hypothesis that talquetamab efficacy may be attenuated in this subgroup. Because t(11;14) frequently co-occurs with high-risk cytogenetic abnormalities (HRCA), we sought to isolate the impact of t(11;14) on clinical outcomes of talquetamab therapy.
Methods
We identified patients with RRMM from the International Myeloma Working Group Immunotherapy Registry who received ≥1 dose of talquetamab and had FISH/cytogenetic testing available prior to treatment. Patients were classified by t(11;14) status (positive/negative). IMWG-HRCA included del(17p), t(4;14), t(14;16), (t14;20). Overall response rate (ORR, ≥PR), very good partial response or better (≥VGPR), and complete response or better (≥CR) were compared by t(11;14) status using logistic regression adjusted for age, sex, ECOG performance status, prior lines of therapy, prior anti-BCMA therapy, and triple-class refractory status. Progression-free survival (PFS) and overall survival (OS) were assessed using Cox regression with the same covariates, stratified by co-occurring HRCA. Kaplan-Meier methods with log-rank testing were used for unadjusted comparisons.
Results
Among 200 patients treated with talquetamab who had complete cytogenetic information, t(11;14)+ in 36 patients (18%) and t(11;14)- in 164 (82%). Baseline characteristics were similar between t(11;14)- and t(11;14)+ patients, including median age (66 vs. 65 years), female sex (49% vs. 58%), median prior lines of therapy (5 vs. 5.5), prior anti-BCMA exposure (66.3% vs. 72.2%), triple-class refractory status (91.4% vs. 97.2%), and ECOG 0–1 performance status (77.2% vs. 85.0%) (all p>.2). As expected, co-occurring HRCA were less frequent in t(11;14)-positive patients (29.4% vs. 48.1%; p=.047), consistent with mutually exclusive nature of IgH translocations. Median follow-up was 28.2 months.
ORR did not differ significantly by t(11;14) status (58.3% positive vs. 64.0% negative; unadjusted p=.52; adjusted OR 1.19, 95% CI 0.37–3.83, p=.77), nor did ≥VGPR (41.7% vs. 47.0%, unadjusted p=.57; adjusted OR 0.79, 95% CI 0.27–2.36, p=.67) or ≥CR (13.9% vs. 20.7%, unadjusted p=.35; adjusted OR 0.76, 95% CI 0.17–3.31, p=.71).
t(11;14) positivity was associated with significantly shorter PFS (median 7.5 vs. 5.6 months; 12-month PFS rate 35% vs. 9%; log-rank p=0.005). Following adjustment for age, sex, ECOG, prior lines of therapy, prior anti-BCMA therapy, and triple-class refractory status, and stratifying by co-occurring HRCA, t(11;14) remained independently associated with shorter PFS (adjusted HR 1.91, 95% CI 1.07–3.40, p=.029).
OS did not differ significantly by t(11;14) status (median 18.6 vs. 20.2 months; log-rank p=.81; adjusted HR 0.76, 95% CI 0.34–1.70, p=.50, HRCA-stratified).
Conclusions
In this large international cohort of RRMM patients treated with talquetamab, the presence of t(11;14) was independently associated with shorter PFS without a corresponding effect on OS. The association remained significant despite adjusting for available clinical parameters and co-occurring HRCA. These findings suggest t(11;14) may affect the durability of disease control achieved with talquetamab and may support consideration of combination therapeutics in this subset of patients.
DISCLOSURES
Susan Bal, MD: AstraZeneca - Honoraria; Amyloid Foundation - Honoraria; MJH Life Sciences - Honoraria; Pfizer - Honoraria; Bristol Myers Squibb/Celgene - Honoraria; Johnson & Johnson - Honoraria; BeiGene - Honoraria; Fate Therapeutics - Honoraria; Bristol Myers Squibb Foundation - Honoraria; Adaptive Biotechnologies, - Honoraria; AbbVie - Honoraria; Kite/Arcellx - Honoraria; Amyloid Foundation - Research Funding; BeiGene - Research Funding; Bristol Myers Squibb Foundation - Research Funding; Johnson & Johnson - Research Funding; MJH Life Sciences - Research Funding; AstraZeneca - Research Funding; Adaptive Biotechnologies, - Research Funding; Kite/Arcellx - Research Funding; AbbVie - Research Funding; Bristol Myers Squibb/Celgene - Research Funding; Pfizer - Research Funding; Fate Therapeutics - Research Funding; GSK - Consultancy (Includes expert testimony); Bristol Myers Squibb/Celgene - Consultancy (Includes expert testimony); Amyloid Foundation - Consultancy (Includes expert testimony); MJH Life Sciences - Consultancy (Includes expert testimony); Adaptive Biotechnologies, - Consultancy (Includes expert testimony); Kite/Arcellx - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Legend Biotech - Consultancy (Includes expert testimony); BeiGene - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Fate Therapeutics - Consultancy (Includes expert testimony); Bristol Myers Squibb Foundation - Consultancy (Includes expert testimony)